Save on Litfulo with Coupons, Discounts & Savings Programs

Litfulo is the brand name for ritlecitinib and is available as an oral capsule.

Litfulo is available as a 50 mg oral capsule.

Litfulo is a JAK kinase and tyrosine kinase inhibitor and is used to treat severe hair loss (alopecia areata) in people ages 12 years and older.

Litfulo is a kinase inhibitor. It works by blocking enzymes (proteins) called Janus kinase (JAK) and tyrosine kinase. This prevents the activation of other proteins in your immune system from attacking hair follicles and causing hair loss.

Litfulo is typically dosed at 50 mg by mouth once daily.

Litfulo is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Litfulo:

• Headache
• Diarrhea
• Acne
• Rash
• Hives

Serious side effects are rare with Litfulo. Contact your healthcare provider immediately if you experience any of the following.

• Stroke: sudden weakness in your body, trouble speaking, confusion, dizziness
• Arterial thrombosis (blood clot in the heart): chest pain; short of breath; pain in the jaw, neck, or back; feeling weak or light-headed
• Pulmonary embolism (blood clot in the lung): cough, chest pain, trouble breathing, racing heart
  Deep vein thrombosis (blood clot in the leg): leg cramp, swelling, pain, muscle tightness
• Serious bleeds: bleed or bruise easily, bleeding that’s hard to stop, coughing blood, stomach pain, blood in urine or stool
• Serious infections: fever, difficulty breathing, diarrhea, weakness, cough, stomach pain, sweating, chills, burning when you urinate, urinating more often
  Allergic reaction: hives, rash, feeling faint, trouble breathing, swelling of your lips or tongue

The following medications may interact with Litfulo:

• Certain CYP3A substrates: Additional monitoring and dose adjustment of CYP3A substrate should be considered.
• Certain CYP1A2 substrates: Additional monitoring and dose adjustment of CYP1A2 substrate should be considered
• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended

Pfizer

It is not known if Litfulo will harm your unborn baby.
Females who are able to become pregnant: Tell your healthcare provider if you are pregnant or plan to become pregnant during treatment with Litfulo. There is a pregnancy registry for people who take Litfulo during pregnancy. Report pregnancies to Pfizer Inc. at 1-877-390-2940.

• Ritlecitinib